Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Polpharma SA
Generics And Biosimilars Industry Reshaped By Transformations
The latest Generics Bulletin Top 50 ranking of global generics and biosimilars companies sees a new name in the top five amid transformations for some of the leading off-patent players. Meanwhile, a number of mid-level firms shift position and newcomers climb into the bottom of the table.
Takeda Feels Confident Of No Entyvio Biosimilars Until Early 2030s
Biosimilar vedolizumab rivals to Takeda’s Entyvio blockbuster will not materialize in the current decade, the Japanese originator has forecasted as part of a significantly extended IP landscape.
Bioeq’s Lucentis Biosimilar Is Given EU Go-Ahead
Bioeq’s Ranivisio ranibizumab biosimilar has gained European Commission authorization for all innovator indications including wet AMD, the leading cause of blindness among over-65s.
COVID-19 Vaccine Skycovion Among Raft Of New EU Filings
EU marketing authorization applications for 12 products, including Skycovion, trastuzumab duocarmazine, alpelisib and sparsenta, are now being evaluated by the European Medicines Agency.
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Polpharma Biologics
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.